800+ High Profile Attendees
Including C-Suites, Heads/ VPs/Directors of Upstream & Downstream Bioprocesssing, R&D, Quality & Compliance, Analytical & more!
The only event in Europe connecting you to Europe’s key biologics, vaccines & cell therapy players with representations from R&D, Manufacturing & Logistics!
50+ Expert Speakers
Presentations on the Latest Manufacturing Technologies, Co-Development Opportunities, Process Development Know-How, Cost Reduction Strategies to Maintain Competitiveness & more.
20+ Hour of Nextworking
During the event and over 6 weeks before and after. Engage in private 1-on-1 chats with 6744 messages exchanged on the event app in the past edition.
Presentations & Posters
Come and listen Emmanuelle Cameau, our Technical Manager Viral Vectors & Gene Therapy expert on Wednesday, October 27th, 2021 @10am
How to Scale Up Viral Vector Production for Gene Therapy Applications
With multiple products approved and commercialized, gene therapy has now gone beyond proof of concept and entered mainstream healthcare. This success urgently requires work on manufacturing processes to ensure that gene therapies are widely available to all that need them.
Pall’s Accelerator℠ process development services help our customers develop reproducible and scalable processes for viral vector manufacturing in order to meet clinical and commercial market demand in very short timelines. We will outline how we work with our customers in providing this service, and present case studies of Adeno-Associated Virus (AAV) and Lentivirus (LV) production using adherent and suspension cell culture. Furthermore, we will present how we can also help our customers build their production facility with virtual reality through our Accelerator Vision platform.
Technical Manager Viral Vectors and Gene Therapy EMEA, Pall Corporation